-+ 0.00%
-+ 0.00%
-+ 0.00%

HEALX: FIRST PATIENT DOSED IN PHASE 1/2 TRIAL OF HLX-4310 FOR RELAPSED, REFRACTORY SARCOMA, WITH A FOCUS ON OSTEOSARCOMA

Reuters·07/22/2026 11:02:57

Please log in to view news